Joint Clinical Trials Office
Assessing the effect of abstinence period on semen analysis parameters
Study Status:
Open to Enrollment
Primary Investigator:
Date: May 17, 2023
Feasibility and Acceptability of a Mobile Cognitive Behavior Therapy App Targeting Depression and Anxiety in Middle Aged and Older Adults
Study Status:
Open to Enrollment
Primary Investigator:
Date: May 11, 2023
The WCM Advancing HIV Health through Epigenetic studies in Aging and Alzheimer's Disease (AHEAD) Study
Study Status:
Open to Enrollment
Primary Investigator:
Date: May 11, 2023
A Phase 1/2 First in Human Study of the Menin-MLL(KMT2A) Inhibitor KO-539 in Patients With Relapsed or Refractory Acute Myeloid Leukemia
Study Status:
Open to Enrollment
Primary Investigator:
Date: May 10, 2023
Multicenter, Open Label, Phase 3 Study of Tabelecleucel for Solid Organ or Allogeneic Hematopoietic Cell Transplant Subjects with Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease after Failure of Rituximab or Rituximab and Chemo
Study Status:
Open to Enrollment
Primary Investigator:
Date: May 10, 2023
A Phase 1, Open-Label, Dose-Escalation and -Expansion Study of the Bruton Tyrosine Kinase-Targeted Protein-Degrader BGB-16673 in Patients With B-Cell Malignancies
Study Status:
Open to Enrollment
Primary Investigator:
Date: May 10, 2023
A multicenter, randomized, open-label, blinded endpoint evaluation, phase 3 study comparing the effect of abelacimab relative to dalteparin on venous thromboembolism (VTE) recurrence and bleeding in patients with gastrointestinal (GI) / genitourinary (GU)
Study Status:
Open to Enrollment
Primary Investigator:
Date: May 10, 2023
A Phase 1/2a Open-label, Dose-escalation, Dose-expansion, Parallel Assignment Study to Evaluate the Safety and Clinical Activity of PBCAR0191 in Subjects with Relapsed/Refractory (r/r) Non-Hodgkin Lymphoma (NHL) and r/r B-cell Acute Lymphoblastic Leukemia
Study Status:
Open to Enrollment
Primary Investigator:
Date: May 10, 2023
A Phase Ib /Randomized Phase III Trial of Patients with Advanced Hematologic Malignancies Undergoing Allogeneic Hematopoietic Cell Transplantation with Either Orca-T, a T-cell-Depleted Graft with Additional Infusion of Conventional T cells and Regulatory
Study Status:
Open to Enrollment
Primary Investigator:
Date: May 10, 2023
Zanubrutinib and venetoclax as initial therapy for CLL with obinutuzumab consolidation in patients with minimal residual disease positivity
Study Status:
Open to Enrollment
Primary Investigator:
Date: May 4, 2023